Therapeutic Solutions International, Inc., Releases Intranasal Formulation of Pterostilbene
July 16 2018 - 9:00AM
InvestorsHub NewsWire
Therapeutic Solutions International,
Inc., Releases
Intranasal Formulation of
Pterostilbene for
Rapid Access to Blood-Brain
Barrier
Company Expands its Pterostilbene Based Portfolio into
Brain Cancers
Oceanside, CA
-- July
16, 2018
--
Investorshub NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) announced
today the release of
NeuroStilbene,
a
proprietary nano-formulation of
pterostilbene formulated for
intranasal delivery.
Intranasal delivery
is used with the intention to deliver high concentrations
of substances into the brain across what is called the "blood-brain
barrier." This structure is a "security system"
that keeps blood cells separate from the fluid surrounding the
brain. This barrier does provide oxygen
and nutrients to be transported by the blood cells but prevents
harmful substances like bacteria or poisons from getting to the
brain. While
compounds
such
as pterostilbene
[1,2], and alpha lipoic acid [3], can bypass the
BBB, it
is anticipated that higher concentrations can be delivered through
the intranasal route.
"Our
pharmacokinetic trial
data showed a 55% increase in serum concentration of nanoparticle
pterostilbene over a powdered and capsule form. We are
therefore pleased to
release a formulation
of this product with
double the potency and half-life over traditional powder
formulation for intranasal use", said
Timothy Dixon, President, and CEO. "Late last year we filed a
patent on the synergistic
inhibition of glioma using pterostilbene. Our data suggest that
when pterostilbene is combined with brain cancer therapeutics such
as Temozolomide, Sertraline, or Gefitinib, their prognosis
is improved. Furthermore, we observed that
pterostilbene causes an increase of immunogenicity in
chemotherapy-treated cancer cells, providing heightened
immunity
to cancer cells that escaped chemotherapy, theoretically
enhancing
patient
prognosis" added Mr.
Dixon.
"The pterostilbene
molecule has numerous potential applications in neurology and
neuro-oncology. The generation of an intranasal formulation of
pterostilbene opens the door for evaluating this molecule in a
rapid manner in glioma and other brain cancer patients, where safe
therapeutics with favorable safety profiles are
urgently
needed" said Dr. Santosh
Kesari, MD, Ph.D.,
and member of the Company's Scientific
Advisory
Board.
"We are working on
integrating NeuroStilbene
into various protocols that are currently in development in order
to enhance therapeutic options to patients with dreaded conditions
such as brain tumors and
neurodegenerative diseases" stated
Dr. James
Veltmeyer, Chief Medical Officer of the Company.
About
Therapeutic Solutions International, Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com.
[1] Activation of the
c-Met pathway mobilizes an inflammatory network in the brain
microenvironment to promote brain metastasis of breast cancer.
Cancer Res. 2016 Sep 1; 76(17): 49704980. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010459/
[2]
Apoptotic and Nonapoptotic Activities of Pterostilbene against Cancer.
Int
J
Mol
Sci. 2018
Jan 18;19(1). http://www.mdpi.com/1422-0067/19/1/287/pdf
[3]
Neuroprotection by the metabolic antioxidant alpha-lipoic acid.
Free Radic
Biol
Med. 1997;22(1-2):359-78.
https://www.ncbi.nlm.nih.gov/pubmed/8958163
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Jul 2023 to Jul 2024